Case 3:15-cv-03107-MAS-LHG Document 4 Filed 05/01/15 Page 1 of 1
`
`PagelD: 44
`
`AO 120 (Rev. 08/10)
`
`TO:
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark
`Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`REPORT ON THE
`AN
`FILING OR DETERMINATION OF
`ACTION REGARDING A PATENT OR
`TRADEMARK
`
`
`In Compliance with 35 U.S.C. § and/or 15 U.S.C. § 1116 you are 290
`
`
`that advised hereby a court action has been
`
`
`filed in the U.S. District Court
`
`
`the for District of New Jersey on
`the
`following:
`Trademarks or X Patents. (
`the patent action
`
`involves 35 U.S.C. 292.)
`§
`
`DOCKET NO.
`3:15-cv-03107-MAS-LHG
`PLAINTIFF
`SANOFI-AVENTIS U.S. LLC
`
`DATE FILED
`15/1/2015
`
`U.S. DISTRICT COURT
`TRENTON. NJ
`DEFENDANT
`ACTAVIS LLC
`
`DATE OF PATENT
`OR TRADEMARK
`JAN. 6. 2015
`
`HOLDER OF PATENT OR TRADEMARK
`
`AVENTIS PHARMA SA
`
`PATENT OR
`TRADEMARK NO
`1 US 8.927.592 B2
`2
`3
`4
`5
`
`In the above—entitled case,
`DATE INCLUDED
`INCLUDED BY
`
`the
`
`following
`
`patent/sV
`
`
`
`trademarks 1 have been included:
`
`PATENT OR
`TRADEMARK NO.
`
`DATE OF PATENT
`ORTRADEMARK
`
`HOLDER OF PATENT OR TRADEMARK
`
`Amendment
`
`Answer
`
`Cross Bill
`
`Other Pleading
`
`1
`2
`3
`4
`5
`
`In the above—entitled case,
`DECISION/JUDGEMENT
`
`the
`
`following
`
`decision
`
`has
`
`been
`
`rendered
`
`or
`
`judgement
`
`CLERK
`William T. Walsh
`
`(BY) DEPUTY CLERK
`s/ Karen McGonigle
`
`DATE
`5/1/2015
`
`copy
`this
`Copy 1—Upon initiation of action, mail
`Copy 2—Upon filing document adding patent(s), mail
`
`to
`this
`
`Director
`copy
`
`3—Upon
`Copy
`to
`Director
`Copy
`
`termination
`4—Case
`
`of
`
`action,
`file copy
`
`00001
`
`MYLAN - EXHIBIT 1004 (Part 1 of 13)
`
`

`

`Case 3:15-cv-02521-MAS-LHG Document 2 Filed 04/06/15 Page 1 of 1
`
`PagelD: 39
`
`AO 120 mev.
`
`08/10)
`
`TO:
`
`Mail Stop 8
`
`Director of the U.S. Patent and Trademark
`Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`TRADEMARK
`
`§ that a court action has been 1116 you are
`
`
`U.S.C.
`15
`and/or
`290
`In Compliance with 35 U.S.C. §
`of New
`Jersey
`the District
`filed in the U.S. District Court
`for
`on
`Trademarks or X Patents. (
`the patent action
`involves 35 U.S.C.
`§
`292.)
`
`
`
`
`
`the
`
`DOCKET NO.
`3:15-cv-02521-MAS-LHG
`PLAINTIFF
`SANOFI-AVENTIS U.S. LLC
`
`DATE FILED
`14/6/2015
`
`U.S. DISTRICT COURT
`TRENTON. NJ
`DEFENDANT
`BPI LABS, LLC
`
`PATENT OR
`TRADEMARK NO.
`1 US 8,927,592 B2
`
`DATE OF PATENT
`OR TRADEMARK
`Jan. 6, 2015
`
`HOLDER OF PATENT OR TRADEMARK
`
`Aventis Parma SA
`
`3
`4
`
`In the above—entitled case,
`DATE INCLUDED
`INCLUDED BY
`
`the
`
`following
`
`patentfsV
`
`trademarkfs)
`
`have
`
`been
`
`included:
`
`PATENT OR
`TRADEMARK NO.
`
`DATE OF PATENT
`OR TRADEMARK
`
`HOLDER OF PATENT OR TRADEMARK
`
`Amendment
`
`Answer
`
`Cross Bill
`
`Other Pleading
`
`1
`2
`3
`4
`5
`
`In the above—entitled case,
`DECISION/JUDGEMENT
`
`the
`
`following
`
`decision
`
`has
`
`been
`
`rendered
`
`or
`
`judgement
`
`CLERK
`William T. Walsh
`
`(BY) DEPUTY CLERK
`s/ Karen McGonigle
`
`DATE
`4/6/2015
`
`to Director
`copy
`Copy 1—Upon initiation of action, mail this
`Copy 2—Upon filing document adding patent(s), mail
`this
`copy
`
`3—Upon
`Copy
`to Director
`
`Copy
`
`termination
`4—Case
`
`of
`
`action,
`file
`
`copy
`
`00002
`
`

`

`Case 3:15-cv-02522-MAS-LHG Document 3 Filed 04/06/15 Page 1 of 1 PagelD: 42
`
`AO 120 (Rev. 08/10)
`
`TO:
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark
`Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`REPORT ON THE
`FILING OR DETERMINATION OF
`ACTION REGARDING A PATENT OR
`TRADEMARK
`
`AN
`
`
`15
`U.S.C. advised that a court action has § 1116 you
`
`
`
`
`and/or
`290
`In Compliance with 35 U.S.C. §
`are been
`the District
`of
`New
`Jersey
`filed in the U.S. District Court
`for
`on
`Trademarks or X Patents. (
`the patent action
`
`involves 35 U.S.C. § 292.)
`
`the
`
`DOCKET NO.
`3:15-cv-02522-MAS-LHG
`PLAINTIFF
`SANOFI-AVENTIS U.S. LLC
`
`DATE FILED
`14/6/2015
`
`U.S. DISTRICT COURT
`TRENTON. NJ
`DEFENDANT
`DR. REDDYS LABORATORIES,
`
`INC.
`
`DATE OF PATENT
`OR TRADEMARK
`Jan. 6, 2015
`
`HOLDER OF PATENT OR TRADEMARK
`
`Aventis Parma SA
`
`PATENT OR
`TRADEMARK NO
`1 US 8,927,592 B2
`2
`3
`4
`5
`
`In the above—entitled case,
`INCLUDED BY
`DATE INCLUDED
`
`the
`
`following
`
`
`
`patent!"sV tradeinark(s') have
`
`been
`
`included:
`
`PATENT OR
`TRADEMARK NO.
`
`DATE OF PATENT
`OR TRADEMARK
`
`HOLDER OF PATENT OR TRADEMARK
`
`Amendment
`
`Answer
`
`Cross Bill
`
`Other Pleading
`
`1
`2
`3
`4
`5
`
`In the above—entitled case,
`DECISION/JUDGEMENT
`
`the
`
`following
`
`decision
`
`has
`
`been
`
`rendered
`
`or
`
`judgement
`
`CLERK
`William T. Walsh
`
`(BY) DEPUTY CLERK
`s/ Karen McGonigle
`
`DATE
`4/6/2015
`
`3—Upon
`Copy
`to Director
`copy
`Copy 1—Upon initiation of action, mail this
`Copy 2—Upon filing document adding patent(s), mail this
`copy
`to Director Copy
`4—Case
`
`termination
`file copy
`
`of
`
`action,
`
`00003
`
`

`

`Case 3:15-cv-02523-MAS-LHG Document 2 Filed 04/06/15 Page 1 of 1
`
`PagelD: 40
`
`AO 120 {Rev. 08/10)
`
`TO:
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark
`Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`REPORT ON THE
`FILING OR DETERMINATION OF
`ACTION REGARDING A PATENT OR
`TRADEMARK
`
`AN
`
`290
`In Compliance with 35 U.S.C. §
`filed in the U.S. District Court
`Trademarks or X Patents. (
`
`1116
`§
`U.S.C.
`15
`and/or
`Jersey
`of New
`the District
`for
`the patent action
`involves 35 U.S.C. §
`
`you
`on
`292.)
`
`are
`the
`
`DATE FILED
`DOCKET NO.
`3:15—cv—02523—MAS—LHG 4/6/2015
`PLAINTIFF
`SANOFI-AVENTIS U.S. LLC
`
`U.S. DISTRICT COURT
`TRENTON. NT
`DEFENDANT
`GLENMARK GENERICS
`
`INC.
`
`DATE OF PATENT
`OR TRADEMARK
`Jan. 6, 2015
`
`HOLDER OF PATENT OR TRADEMARK
`
`Aventis Parma SA
`
`PATENT OR
`TRADEMARK NO.
`1 US 8,927,592 B2
`2
`3
`4
`5
`
`In the above—entitled case,
`DATE INCLUDED
`INCLUDED BY
`
`the
`
`following
`
`
`
`patentCsV trademark(s)
`
`have
`
`been
`
`included:
`
`PATENT OR
`TRADEMARK NO
`
`DATE OF PATENT
`OR TRADEMARK
`
`HOLDER OF PATENT OR TRADEMARK
`
`Amendment
`
`Answer
`
`Cross Bill
`
`Other Pleading
`
`1
`2
`3
`4
`5
`
`In the above—entitled case,
`DECISION/JUDGEMENT
`
`the
`
`following
`
`decision
`
`has
`
`
`
`rendered been judgement issued:
`
`
`
`or
`
`CLERK
`William T. Walsh
`
`(BY) DEPUTY CLERK
`s/ Karen McGonigle
`
`DATE
`4/6/2015
`
`3—Upon
`Copy
`Director
`to
`copy
`Copy 1—Upon initiation of action, mail this
`
`
`Copy 2—Upon filing document adding patent(s), mail this copy to Director Copy 4—Case file copy
`
`termination
`
`of
`
`action,
`
`00004
`
`

`

`Case 3:15-cv-02631-MAS-LHG Document 3 Filed 04/13/15 Page 1 of 1 PagelD: 44
`
`AO 120 (Rev. 08/10)
`
`TO:
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark
`Office
`P.O. Box 1450
`Alexandria, VA 22313 1450
`
`REPORT ON THE
`FILING OR DETERMINATION OF
`ACTION REGARDING A PATENT OR
`TRADEMARK
`
`AN
`
`In Compliance with 35 U.S.C. §
`290
`filed in the U.S. District Court
`Trademarks or X Patents. (
`
`§ that a court action has been 1116 you
`
`
`U.S.C.
`15
`and/or
`
`
`New of the District Jersey on the following:
`for
`
`the patent action
`
`involves 35 U.S.C. § 292.)
`
`
`
`are
`
`DOCKET NO.
`DATE FILED
`3:15—cv—02631 -M A S-LHG14/13/2015
`PLAINTIFF
`SANOFI-AVENTIS U.S. LLC
`
`U.S. DISTRICT COURT
`TRENTON. N.T
`DEFENDANT
`FRESENIUS KABI USA, LLC
`
`DATE OF PATENT
`OR TRADEMARK
`Jan. 6, 2015
`
`HOLDER OF PATENT OR TRADEMARK
`
`Aventis Parma SA
`
`PATENT OR
`TRADEMARK NO
`1 US 8,927,592 B2
`2
`3
`4
`5
`
`In the above—entitled
`DATE INCLUDED
`INCLUDED BY
`
`case,
`
`the
`
`following
`
`
`
`patent(s )/ trademark^ s ) have been included:
`
`Amendment
`
`Answer
`
`Cross Bill
`
`Other Pleading
`
`DATE OF PATENT
`OR TRADEMARK
`
`HOLDER OF PATENT OR TRADEMARK
`
`PATENT OR
`TRADEMARK NO
`1
`2
`3
`4
`5
`
`In the above—entitled case,
`DECISION/JUDGEMENT
`
`the
`
`following
`
`decision
`
`has
`
`
`
`been judgement issued: rendered
`
`
`
`or
`
`CLERK
`William T. Walsh
`
`(BY) DEPUTY CLERK
`s/ Karen McGonigle
`
`DATE
`4/13/2015
`
`copy
`this
`initiation of action, mail
`Copy 1—Upoa
`Copy 2—Upon filing document adding patent(s), mail
`
`to
`this
`
`Director
`copy
`
`termination copy to Director
`3—Upon
`Copy
`
`to
`Director
`Copy
`4—Case
`
`of
`
`action,
`file copy
`
`00005
`
`

`

`Case 3:15-cv-01836-MAS-LHG Document 4 Filed 03/11/15 Page 1 of 1 PagelD: 20
`
`AO 120 fRev. 08/10)
`
`TO:
`
`Mail Stop 8
`Director of the U.S. Patent
`Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`
`
`and Trademark
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`TRADEMARK
`
`hereby advised that a court action has been
`and/or 290 15 U.S.C. § 1116 you are
`
`
`In Compliance with 35 U.S.C. §
`
`filed in the U.S. District Court
`for
`the District
`of
`New
`Jersey
`on
`the patent action
`
`involves 35 U.S.C. § 292.)
`Trademarks or X Patents. (
`
`the
`
`DOCKET NO.
`DATE FILED
`3:15-cv-01836-MAS-LHGI3/11/2015
`PLAINTIFF
`SANOFI-AVENTIS U.S. LLC
`
`U.S. DISTRICT COURT
`TRENTON. NJ
`DEFENDANT
`BRECKENRIDGE PHARMACEUTICAL,
`
`INC.
`
`DATE OF PATENT
`OR TRADEMARK
`1/6/2015
`
`HOLDER OF PATENT OR TRADEMARK
`
`Aventis Pharma S.A.
`
`PATENT OR
`TRADEMARK NO.
`1 8,927,592
`2
`3
`4
`5
`
`In the above—entitled case,
`DATE INCLUDED
`INCLUDED BY
`
`the
`
`following
`
`patentfsV
`
`trademark(s) have
`
`been
`
`included:
`
`Amendment
`
`Answer
`
`Cross Bill
`
`Other Pleading
`
`DATE OF PATENT
`OR TRADEMARK
`
`HOLDER OF PATENT OR TRADEMARK
`
`PATENT OR
`TRADEMARK NO
`1
`2
`3
`4
`5
`
`In the above—entitled case,
`DECISION/JUDGEMENT
`
`the
`
`following
`
`decision
`
`has
`
`been
`
`rendered
`
`or
`
`judgement
`
`CLERK
`William T. Walsh
`
`(BY) DEPUTY CLERK
`s/ Karen McGonigle
`
`DATE
`3/11/2015
`
`Copy 1—Upon initiation of action, mail this copy to Director Copy 3—Upon termination of action, mail
`
`
`Copy 2—Upon filing document adding patent(s), mail
`this
`
`copy Copy 4—Case file copy to Director
`
`
`
`
`
`this copy to Director
`
`00006
`
`

`

`^ UNITED STATES PATENT AND TRADEMARK OFFICE
`1
`
`it
`1
`
`•AT OF CO
`
`UNITED STATES DEPARTMENT OF
`COMMERCE
`United States Patent
`and
`Trademark
`Office
`Address: COMMISSIONER
`FOR
`PATENTS
`P.O. Bo DX 1450
`dria, Virginia 22313-1450
`Alexan
`to.gov
`www.usp
`
`APPLICATION NO.
`
`13/456,720
`
`ISSUE DATE
`
`01/06/2015
`
`PATENT NO.
`
`ATTORNEY DOCKET
`
`NO.
`
`CONFIRMATION NO.
`
`8927592
`
`FR2009/121 US CNT
`
`1083
`
`12/17/2014
`
`5487
`7590
`ANDREA Q. RYAN
`SANOFI
`55 Corporate Drive
`MAIL CODE: 55A-505A
`BRIDGEWATER, NJ 08807
`
`ISSUE NOTIFICATION
`
`The projected patent number
`
`and
`
`issue
`
`date
`
`are
`
`specified
`
`above.
`
`Determination of Patent Term Adjustment under
`(application filed on or
`after May
`
`35 U.S.C.
`29,
`2000)
`
`154
`
`(b)
`
`The Patent Term Adjustment is 0 day(s). Any patent to issue from
`
`an indication of the adjustment on the
`front
`page.
`
`the above-identified application will include
`
`If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that
`determines Patent Term Adjustment
`is
`the
`
`date filing the most recent CPA.
`
`of
`
`Applicant will be able to obtain more detailed information by accessing the Patent Application Information
`Retrieval (PAIR) WEB
`site
`(http://pair.uspto.gov).
`
`Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the
`Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee
`payments should be directed to the Application Assistance Unit (AAU) of the Office of Data Management
`(ODM) at (571)-272-4200.
`
`APPLICANT(s)
`
`(Please see PAIR WEB site http://pair.uspto.gov for additional applicants):
`
`Sunil GUPTA, Chester Springs, PA;
`
`is location
`world an unparalleled and
`
`
`
`the
`in
`largest, most dynamic marketplace
`
`represents the
`The United States
`for business investment, innovation, and commercialization of new technologies. The USA offers tremendous
`resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation
`works to encourage and facilitate business
`
`
`To investment. learn more about why the USA is the best country
`in
`the world to develop
`technology, manufacture
`
`products, your business, visit SelectUSA.gov. and grow
`
`
`
`IR103 (Rev. 10/09)
`
`00007
`
`

`

`App.No. 13/456,720
`
`Atty. Dkt. FR2009/121 US
`
`CNT
`
`CI.hange(s)
`
`applied
`Replace the paragraph
`
`the
`
`following
`
`rewritten
`
`paragraph:
`
`Amendments to the Specification
`5
`J>,
`at
`
`page line 11 with
`to document,
`/K-W./
`patients
`of
`proportion
`the
`depicts
`Figure 4 graphically
`i 2/5/201 +
`
`population). The "Improved"
`treatment
`(safety
`performance status
`from baseline during
`
`0 The "stable" column or
`
`to
`column represents PS2
`at
`baseline
`changed
`represents no change,
`
`
`and
`the
`"Worse"
`
`column PS2 at baseline and represents changed
`or 0 or 1 at baseline
`
`> to changed 2 during treatment.
`
`
`
`with
`
`1
`>
`
`to
`
`5
`Replace the paragraph
`following
`the
`page line 24 with
`at
`
`paragraph:
`rewritten
`depicts
`the
`proportion
`of
`Figure 5 graphically
`patients
`with
`score
`during
`
`
`the Present Pain
`Intensity
`
`treatment (ITT). "Improved" column The represents
`
`patients in which
`
`PPI the score during
`treatment was
`lower
`
`versus The "Stable" baseline.
`
`column represents
`no
`change,
`and "Worse" column the
`
`
`represents
`patients
`with
`increase in PPI score
`during
`treatment
`versus
`baseline.
`
`>1
`
`Sanofi US 1041 Route 202-206,
`
`Mail
`
`Code: BWD-303A,
`
`
`
`Bridgewater, Jersey 08807, U.S.A. vvww.sanof;.Lis New
`
`
`
`00008
`
`

`

`PART B - FEE(S) TRANSMITTAL
`Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE
`Commissioner for Patents
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`or Fax (571)-273-2885
`INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where
`appropriate. All further correspondence
`including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as
`indicated unless corrected below or directed otherwise
`in Block 1, by (a) specifying a new correspondence
`address; and/or (b) indicating a separate "FEE ADDRESS" for
`fee
`notifications.
`maintenance
`
`CURRENT CORRESPONDENCE
`
`ADDRESS
`
`(Note:
`
`Use
`
`Block
`
`11/14/2014
`
`5487
`7590
`ANDREA Q. RYAN
`SANOFI
`55 Corporate Drive
`MAIL CODE: 55A-505A
`BRIDGEWATER, NJ 08807
`
`Note: A certificate of mailing can only be used for domestic mailings of the
`Fee(s) Transmittal. This
`
`certificate cannot be used for any other accompanying
`papers. Each additional paper, such as an assignment or
`formal drawing, must
`1
`for
`any
`
`
`of have its own certificate mailing or
`transmission.
`
`Transmission
`or
`Certificate of Mailing
`is being deposited with the United
`I hereby certify that this Fee(s) Transmittal
`States Postal Service
`
`with sufficient postage
`
`for first class mail in an envelope
`addressed to the Mail Stop ISSUE FEE address above, or being facsimile
`transmitted
`to
`the USPTO
`
`on (571) 273-2885, the date indicated
`
`below.
`
`(Depositor's name)
`
`(Signature)
`
`(Date)
`
`APPLICATION NO.
`
`FILING DATE
`
`FIRST NAMED INVENTOR
`
`ATTORNEY DOCKET NO. CONFIRMATION NO.
`
`13/456,720
`TITLE OF
`INVENTION:
`
`04/26/2012
`NOVEL
`ANTITUMORAL
`
`Sunil GUPTA
`USE
`OF
`
`FR2009/121 US CNT
`CABAZITAXEL
`
`1083
`
`APPLN. TYPE
`
`ENTITY STATUS
`
`ISSUE FEE DUE
`
`PUBLICATION FEE DUE PREV. PAID ISSUE FEE TOTAL FEE(S) DUE
`
`DATE DUE
`
`nonprovisional
`
`UNDISCOUNTED
`
`$960
`
`$0
`
`$0
`
`$960
`
`02/17/2015
`
`EXAMINER
`
`ART UNIT
`
`CLASS-SUBCLASS
`
`ANDERSON,
`
`JAMES
`
`D
`
`1629
`
`514-449000
`
`address
`
`or
`
`indication
`
`(or
`address
`attached.
`(or
`"Fee
`or
`more
`
`Change
`
`of
`
`Address"
`recent)
`
`(37
`1 Kelly L. Bender
`
`(having 2-
`
`as
`
`a
`
`member
`
`Customer
`
`1. Change of correspondence
`CFR 1.363).
`Q Change of correspondence
`Address form PTO/SB/122)
`Q "Fee Address" indication
`PTO/SB/47; Rev 03-02
`Number is
`required.
`type)
`BE or
`(print
`TO THE PATENT
`ON
`PRINTED
`
`
`DATA
`RESIDENCE
`AND
`3. ASSIGNEE NAME
`PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for
`set
`forth
`in
`
`
`3.11. CFR 37 Completion of this form is NOT a
`
`substitute
`for
`filing
`an
`assignment.
`recordation as
`(A) NAME OF ASSIGNEE
`(B) RESIDENCE:
`(CITY
`and
`STATE
`OR
`COUNTRY)
`
`Address"
`"Fee
`of
`the
`patent
`
`front page, list
`2. For printing on
`(1) The names of up to 3 registered patent attorneys
`Correspondence
`or agents OR, alternatively,
`
`firm
`(2) The name of a
`single
`registered attorney or agent) and the names of up to
`Indication
`form
`2 registered patent attorneys
`
`or agents. If no name is 3
`Use
`of
`a
`attached.
`listed, no name will be
`printed.
`"
`
`Aventis Pharma
`
`SA
`
`Please check
`
`the appropriate
`
`assignee
`
`category
`
`4a. The following
`fee(s)
`• Issue Fee
`H Publication Fee
`small
`(No
`Q Advance Order - #
`of Copies
`
`are
`
`submitted:
`
`entity
`
`discount
`
`
`
`or be printed on
`
`
`
`
`
`Antony, France
`Q Individual I Corporation or
`categories the patent):
`(will
`not
`
`(Please reapply any previously first
`
`4b. Payment of Fee(s):
`Q A check is enclosed.
`Q Payment by credit
`Form
`card.
`attached.
`PTO-2038
`permitted)
`B The director
`authorized
`is hereby
`required or credits any
`
`the
`charge
`to
`1 8-1 982
`overpayment,
`to Deposit
`Account
`copy
`
`of form).
`Number
`(enclose an extra
`
`other
`
`private
`
`paid
`
`issue
`
`Q Government
`group
`entity
`fee
`
`shown
`
`is
`
`this
`
`5. Change
`in Entity
`Status
`Q Applicant certifying micro
`Q Applicant asserting
`Q Applicant changing
`
`to
`
`(from
`entity
`
`status
`status. CFR 1.29
`
`
`
`
`small entity status. See
`
`37
`
`CFR
`
`regular undiscounted
`
`fee
`
`indicated above)
`Status issue
`
`Entity
`of Micro
`certification
`valid
`a
`
`See NOTE: Absent 37
`
`
`
`not application abandonment. be
`will
`amount
`entity
`the micro
`fee payment
`in
`1.27
`
`entity checking status, this box will be taken
`
`
`NOTE: If the application was previously under micro
`status.
`to be a notification
`of
`
`
`of loss entitlement
`to micro
`entity
`status.
`NOTE: Checking
`this box will be taken
`to be
`a
`
`notification of loss of entitlement to small or micro
`entity status, as
`applicable.
`
`accordance 1.31 and 1.33. See
`
`with 37
`CFR
`
`
`NOTE: This
`form must
`be
`signed
`in
`Authorized Signature /Kelly L. Bdldcr/
`Typed or printed name Kelly L. Bender
`
`37 1.4
`
`
`CFR for
`signature
`November 20, 2014
`Registration No. 52,61 0
`
`Date
`
`requirements
`
`and
`
`PTOL-85 Part B
`
`(10-13)
`
`Approved
`
`
`
`for 10/31/2013. use
`
`
`
`Page 2 of 3
`
`through
`OMB 0651-0033 U.S. Patent and Trademark
`
`Office;
`
`U.S.
`
`DEPARTMENT
`
`00009
`
`

`

`Electronic Patent Application Fee Transmittal
`
`Application Number:
`
`Filing Date:
`
`13456720
`
`26-Apr-2012
`
`Title of Invention:
`
`NOVEL ANTITUMORAL USE OF CABAZITAXEL
`
`First Named Inventor/Applicant
`
`Name:
`
`Sunil GUPTA
`
`Filer:
`
`Kelly L. Bender/Brian
`
`Pritchett
`
`Attorney Docket
`
`Number:
`
`FR2009/121 USCNT
`
`Filed as Large Entity
`
`Utility under
`
`35 USC 111 (a) Filing Fees
`
`Description
`
`Fee Code
`
`Quantity
`
`Amount
`
`Sub-Total
`USD($)
`
`in
`
`Basic Filing:
`
`Pages:
`
`Claims:
`
`Miscellaneous-Filing:
`
`Petition:
`
`Patent-Appeals-and-lnterference:
`
`Post-Allowance-and-Post-lssuance:
`
`Utility Appl
`
`Issue Fee
`
`Publ. Fee- Early, Voluntary, or Normal
`
`1501
`
`1504
`
`1
`
`1
`
`960
`
`0
`
`960
`
`0
`
`00010
`
`

`

`Description
`
`Fee Code
`
`Quantity
`
`Amount
`
`Sub-Total
`USD($)
`
`in
`
`Extension-of-Time:
`
`Miscellaneous:
`
`Total in USD ($)
`
`960
`
`00011
`
`

`

`Electronic Acknowledgement Receipt
`
`EFSID:
`
`Application Number:
`
`20750442
`
`13456720
`
`International Application
`
`Number:
`
`Confirmation Number:
`
`1083
`
`Title of Invention:
`
`NOVEL ANTITUMORAL USE OF CABAZITAXEL
`
`First Named Inventor/Applicant
`
`Name:
`
`Sunil GUPTA
`
`Customer Number:
`
`5487
`
`Filer:
`
`Kelly L. Bender/Brian
`
`Pritchett
`
`Filer Authorized
`
`By:
`
`Kelly L. Bender
`
`Attorney Docket
`
`Number:
`
`FR2009/121 USCNT
`
`Receipt Date:
`
`Filing Date:
`
`Time Stamp:
`
`20-NOV-2014
`
`26-APR-2012
`
`11:37:25
`
`Application Type:
`
`Utility under 35 USC 111(a)
`
`Payment information:
`
`Submitted with Payment
`
`Payment Type
`
`Payment was successfully received
`
`in RAM
`
`RAM confirmation Number
`
`Deposit Account
`
`Authorized User
`
`File Listing:
`
`Document
`Number
`
`yes
`
`Deposit Account
`
`$960
`
`10114
`
`181982
`
`Document Description
`
`File Name
`
`File Size( Bytes)/
`Message Digest
`
`Multi
`Part /.zip
`
`Pages
`(ifappl.)
`
`00012
`
`

`

`1
`
`Miscellaneous
`
`Incoming
`
`Letter
`
`FR2009-121 USCNT_20141120.
`COT.pdf
`
`111479
`
`7d4eb12a82b4d85c36faff7153a3d5fc81f83
`e89
`
`Warnings:
`
`Information:
`
`2
`
`Issue Fee Payment (PTO-85B)
`
`FR2009-121 USCNT_20141120J
`FD.pdf
`
`96479
`
`6 cf5742e9cfc497042961755409c15f91fd9f
`ea4
`
`Warnings:
`
`Information:
`
`no
`
`no
`
`1
`
`1
`
`3
`
`Fee Worksheet
`
`(SB06)
`
`fee-info.pdf
`
`no
`
`2
`
`31975
`
`4d6d6e62a7cf2b77ace15d24efa690e074fa
`83a7
`
`Warnings:
`
`Information:
`
`This Acknowledgement
`evidences receipt on
`
`Receipt
`characterized
`by
`the applicant, and including
`
`page
`Post Card, as described
`in MPEP 503.
`
`the
`noted by the USPTO of date
`
`the
`
`
`counts, where applicable.
`It serves as evidence
`
`indicated
`of receipt
`
`documents,
`
`
`similar to a
`
`
`
`Total Files Size (in bytes):
`
`239933
`
`35 Under U.S.C. 111
`
`
`New Applications
`necessary components for a filing date (see 37 CFR
`the
`
`includes
`the application
`
`
`
`being is filed and
`If a new application
`will
`be course and
`
`the issued date shown on
`
`
`this
`CFR 1.54)
`
`1.53(b)-(d) and
`MPEP 506), a Filing Receipt
`(37
`Acknowledgement
`Receipt
`
`establish will the filing date
`
`
`the of application.
`
`
`
`in
`
`under
`Application
`National Stage of an International
`international
`If a timely
`
`
`submission enter
`to the national
`stage of an
`U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903
`national stage submission
`under
`35
`
`
`U.S.C. 371 will be issued
`in
`
`371
`U.S.C.
`35
`of 35
`the conditions
`
`
`application compliant with is
`
`of
`indicating
`
`acceptance application
`as a
`
`to addition Filing Receipt,
`in due
`the
`course.
`
`
`
`with a Receiving Office the
`
`
`Application
`New International
`as
`USPTO
`
`
`is international being
`
`filed application
`If a new
`international
`application
`
`includes and the necessary components for
`
`an international
`filing
`
`date (see PCT Article 11 and MPEP 1810), a Notification
`of the International Application Number
`and of the
`International
`Filing
`Date
`(Form
`
`PCT/RO/105) subject to prescriptions
`
`
`will concerning
`national
`security, and the date shown on
`this Acknowledgement
`Receipt
`will
`
`establish international
`filing
`
`
`the date of
`the application.
`
`Filed
`
`be
`
`00013
`
`

`

`IN THE UNITED STATES
`
`PATENT
`
`AND
`
`TRADEMARK
`
`OFFICE
`
`Sanofi Docket No.
`
`FR2009/121
`
`US
`
`CNT
`
`In re Application
`GUPTA, et
`al.
`
`of:
`
`Application No.:
`13/456,720
`
`Filed:
`April 26, 2012
`
`Examiner:
`James D. Anderson
`
`Art Unit:
`1629
`
`Title: NOVEL ANTITUMORAL
`
`USE
`
`OF
`
`CABAZITAXEL
`
`TRANSMISSION
`EFS-WEB
`CERTIFICATE OF
`I hereby certify that the correspondence
`below is being transmitted via the
`USPTO's
`electronic
`filing
`system
`in
`accordance
`
`with
`
`1.6(a)(4),
`
`November 20.
`Date of Deposit
`
`2014
`
`/Brian Pritchett/
`Signature
`
`Patents
`
`TO: Commissioner
`for
`P. O. Box 1450
`Alexandria, VA
`
`22313-1450
`
`Attached are
`
`the
`
`following documents:
`
`• Application Data Sheet
`• Declaration
`• Drawings
`• Extension of Time
`• Information Disclosure
`• Response to
`• Specification, Claims
`
`1449
`
`Statement
`
`Number of Pages
`
`and
`
`Form
`
`and
`
`Abstract
`
`Specification
`Claims
`Abstract
`
`FEE
`
`1
`
`• Transmittal Letter:
`• Other (specify):
`• Other (specify):
`
`Other (specify):
`
`ISSUE
`
`Sanofi, 55 Corporate Drive,Mail
`
`Stop:
`
`55A-505A,
`
`Bridgewater,
`
`
`
`New www.sanofi.com
`
`Jersey
`
`08807,
`
`00014
`
`

`

`SjS^igN
`
`£3 9/
`i
`i
`$
`
`l!
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`UNITED STATES DEPARTMENT OF
`United States Patent and Trademark Office
`Address: COMMISSIONER
`FOR
`PATENTS
`
`DX 1450 P.O. Bo
`dria, Virginia 22313-1450
`Alexan
`
`to.gov www.usp
`
`COMMERCE
`
`NOTICE OF ALLOWANCE AND FEE(S)
`
`DUE
`
`11/14/2014
`
`5487
`7590
`ANDREA Q. RYAN
`SANOFI
`55 Corporate Drive
`MAIL CODE: 55A-505A
`BRIDGEWATER, NJ 08807
`
`EXAMINER
`
`ANDERSON,
`
`JAMES
`
`D
`
`ART UNIT
`
`PAPER NUMBER
`
`1629
`
`DATE MAILED:
`
`11/14/2014
`
`APPLICATION NO.
`
`FILING DATE
`
`FIRST NAMED INVENTOR
`
`ATTORNEY DOCKET NO. CONFIRMATION NO.
`
`13/456,720
`TITLE OF
`INVENTION:
`
`04/26/2012
`NOVEL
`ANTITUMORAL
`
`Sunil GUPTA
`USE
`OF
`
`FR2009/121 US CNT
`CABAZITAXEL
`
`1083
`
`APPLN. TYPE
`
`ENTITY STATUS
`
`ISSUE FEE DUE
`
`PUBLICATION FEE DUE PREV. PAID ISSUE FEE TOTAL FEE(S) DUE
`
`DATE DUE
`
`nonpro visional
`
`UNDISCOUNTED
`
`$960
`
`$0
`
`$0
`
`$960
`
`02/17/2015
`
`THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT.
`PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS.
`THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON
`PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.
`THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE
`MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED.
`THIS
`STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES
`NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION.
`IF AN ISSUE FEE HAS
`PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM
`WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW
`DUE.
`
`I. Review the ENTITY STATUS shown above. If the ENTITY STATUS is
`
`shown as
`
`SMALL or MICRO, verify whether entitlement to
`
`that
`
`HOW TO REPLY TO THIS NOTICE:
`
`entity status still applies.
`If the ENTITY STATUS is the same as shown above, pay the TOTAL FEE(S) DUE shown above.
`If the ENTITY STATUS is changed from that shown above, on PART B - FEE(S) TRANSMITTAL, complete section number 5
`"Change in Entity Status (from status indicated above)".
`For purposes of this notice, small entity fees are 1/2 the amount of undiscounted fees, and micro entity fees are 1/2
`fees.
`
`titled
`
`the amount of small entity
`
`II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office
`(USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b"
`of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a
`request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing
`the paper as an equivalent of Part B.
`III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to
`Mail Stop ISSUE FEE unless advised to the contrary.
`IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of
`maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.
`
`PTOL-85 (Rev. 02/11)
`
`Page 1 of 3
`
`00015
`
`

`

`PART B - FEE(S) TRANSMITTAL
`Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE
`Commissioner for Patents
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`or Fax (571)-273-2885
`INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where
`appropriate. All further correspondence
`including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as
`indicated unless corrected below or directed otherwise
`in Block 1, by (a) specifying a new correspondence
`address; and/or (b) indicating a separate "FEE ADDRESS" for
`fee
`notifications.
`maintenance
`
`CURRENT CORRESPONDENCE
`
`ADDRESS
`
`(Note:
`
`Use
`
`Block
`
`11/14/2014
`
`5487
`7590
`ANDREA Q. RYAN
`SANOFI
`55 Corporate Drive
`MAIL CODE: 55A-505A
`BRIDGEWATER, NJ 08807
`
`Note: A certificate of mailing can only be used for domestic mailings of the
`Fee(s) Transmittal. This
`
`certificate cannot be used for any other accompanying
`papers. Each additional paper, such as an assignment or
`formal drawing, must
`1
`for
`any
`
`
`of have its own certificate mailing or
`transmission.
`
`Transmission
`or
`Certificate of Mailing
`is being deposited with the United
`I hereby certify that this Fee(s) Transmittal
`States Postal Service
`
`with sufficient postage
`
`for first class mail in an envelope
`addressed to the Mail Stop ISSUE FEE address above, or being facsimile
`transmitted
`to
`the USPTO
`
`on (571) 273-2885, the date indicated
`
`below.
`
`(Depositor's name)
`
`(Signature)
`
`(Date)
`
`APPLICATION NO.
`
`FILING DATE
`
`FIRST NAMED INVENTOR
`
`ATTORNEY DOCKET NO. CONFIRMATION NO.
`
`13/456,720
`TITLE OF
`INVENTION:
`
`04/26/2012
`NOVEL
`ANTITUMORAL
`
`Sunil GUPTA
`USE
`OF
`
`FR2009/121 US CNT
`CABAZITAXEL
`
`1083
`
`APPLN. TYPE
`
`ENTITY STATUS
`
`ISSUE FEE DUE
`
`PUBLICATION FEE DUE PREV. PAID ISSUE FEE TOTAL FEE(S) DUE
`
`DATE DUE
`
`nonprovisional
`
`UNDISCOUNTED
`
`$960
`
`$0
`
`$0
`
`$960
`
`02/17/2015
`
`EXAMINER
`
`ART UNIT
`
`CLASS-SUBCLASS
`
`ANDERSON,
`
`JAMES
`
`D
`
`1629
`
`514-449000
`
`address
`
`or
`
`indication
`
`(or
`address
`attached.
`(or
`"Fee
`or
`more
`
`Change
`
`Address"
`recent)
`
`of
`
`Address"
`"Fee
`of
`the
`patent
`
`front page, list
`2. For printing on
`(1) The names of up to 3 registered patent attorneys
`Correspondence
`or agents OR, alternatively,
`
`firm
`(2) The name of a
`single
`registered attorney or agent) and the names of up to
`Indication
`form
`2 registered patent attorneys
`
`or agents. If no name is 3
`Use
`of
`a
`attached.
`listed, no name will be
`printed.
`"
`
`1. Change of correspondence
`CFR 1.363).
`Q Change of correspondence
`Address form PTO/SB/122)
`Q "Fee Address" indication
`PTO/SB/47; Rev 03-02
`Number is
`required.
`type)
`BE or
`(print
`TO THE PATENT
`ON
`PRINTED
`
`
`DATA
`RESIDENCE
`AND
`3. ASSIGNEE NAME
`PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for
`set
`forth
`in
`
`
`3.11. CFR 37 Completion of this form is NOT a
`
`substitute
`for
`filing
`an
`assignment.
`recordation as
`(A) NAME OF ASSIGNEE
`(B) RESIDENCE:
`(CITY
`and
`STATE
`OR
`COUNTRY)
`
`1
`
`(having 2-
`
`(37
`
`as
`
`a
`
`Customer
`
`member
`
`Please check
`
`the appropriate
`
`assignee
`
`category
`
`fee(s)
`
`4a. The following
`Q Issue Fee
`Q Publication Fee
`Q Advance Order - #
`
`are
`
`submitted:
`
`small (No entity discount permitted)
`
`
`of Copies
`
`
`
`or be printed on
`
`
`
`
`
`Q Individual Q Corporation or
`categories the patent):
`(will
`not
`
`(Please reapply any previously first
`
`4b. Payment of Fee(s):
`Q A check is enclosed.
`Q Payment by credit
`Form
`card.
`Q The director
`authorized
`is hereby
`overpayment,
`to Deposit
`Account
`
`other
`
`group entity Q Government
`private
`paid
`issue
`fee
`
`shown
`
`attached.
`PTO-2038
`required or credits any
`
`the
`charge
`to
`copy
`
`of form).
`(enclose an extra
`Number
`
`is
`
`this
`
`5. Change
`in Entity
`Status
`Q Applicant certifying micro
`Q Applicant asserting
`Q Applicant changing
`
`to
`
`(from
`entity
`
`status
`status. CFR 1.29
`
`
`
`
`small entity status. See
`
`37
`
`CFR
`
`indicated above)
`Status issue
`
`Entity
`of Micro
`certification
`valid
`a
`
`See NOTE: Absent 37
`
`
`
`not application abandonment. be
`will
`amount
`entity
`the micro
`fee payment
`in
`1.27
`
`entity checking status, this box will be taken
`
`
`NOTE: If the application was previously under micro
`status.
`to be a notification
`of
`
`
`of loss entitlement
`to micro
`entity
`status.
`NOTE: Checking
`this box will be taken
`to be
`a
`
`notification of loss of entitlement to small or micro
`entity status, as
`applicable.
`
`accordance 1.31 and 1.33. See
`
`with 37
`CFR
`
`
`regular undiscounted
`
`fee
`
`NOTE: This
`
`form must
`
`be
`
`signed
`
`in
`
`Authorized Signature
`
`Typed or printed
`
`name
`
`PTOL-85 Part B
`
`(10-13)
`
`Approved
`
`
`
`for 10/31/2013. use
`
`
`
`37 1.4
`
`
`
`CFR for
`
`signature
`
`requirements
`
`and
`
`Date
`
`Registration No.
`
`Page 2 of 3
`
`through
`OMB 0651-0033 U.S. Patent and Trademark
`
`Office;
`
`U.S.
`
`DEPARTMENT
`
`00016
`
`

`

`SjS^igN
`
`£3 9/
`i
`i
`$
`
`l!
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`UNITED STATES DEPARTMENT OF
`United States Patent and Trademark Office
`Address: COMMISSIONER
`FOR
`PATENTS
`
`DX 1450 P.O. Bo
`dria, Virginia 22313-1450
`Alexan
`
`to.gov www.usp
`
`COMMERCE
`
`APPLICATION NO.
`
`FILING DATE
`
`FIRST NAMED
`
`INVENTOR
`
`ATTORNEY DOCKET
`
`NO. CONFIRMATION NO.
`
`13/4